Get started

IBB

EXCLUSIVE EWTX 350% BUY/HOLD techs/fundies with catalyst🔸Let's review EWTX daily price chart. Strong V-shape recovery in progress. YTD gains at 218% off the lows, which is an EXCELLENT indicator of the overall health of the stock. Trading 5% below 52 week high. 🔸Based on technicals, I envision a C*H breakout in 2025 after we hit overhead resistance we can expect a pullback in order to fill the massive liquidity gap left behind near 22 USD. currently stock is trading near 35 handle and expecting limited upside going forward into Q4 2024. Market cap is hovering near 3 Bln USD so it's not a penny stock and also market cap is not inflated. 🔸CYTK competitor stock chart on the right, similarly priced and also same line of business as EWTX. Trading at 53 USD now previously maxed out at 100 USD, current CYTK market cap is 6 Bln USD, at the peak market cap was 12 Bln USD. So potentially EWTX can do x4 from current levels in order to hit CYTK max market cap. this means x4 stock prices for EWTX from current levels, so it's 34 x 4 = 136 USD max projected stock price. 🔸My PT for EWTX in 2025 is 100 USD, based on the technicals and fundamentals. Recommended strategy bulls: wait for pullback/rejection from overhead resistance and be ready to BUY/HOLD once we do a COMPLETE gap fill of the liquidity gap near 22 USD. Target is 100 USD, 350%+ upside from entry price. Good luck traders! 🔸Below supplementary fundies info on EWTX / some info on the positive catalysts, you can dig deeper if required. 🔸Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for serious muscle diseases, particularly rare neuromuscular and cardiac disorders. Founded in 2017 and headquartered in Boulder, Colorado, the company leverages its deep expertise in muscle biology to create innovative therapies aimed at unmet medical needs. 🔸Their lead product candidate, EDG-5506, is being developed to treat Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD). This small molecule is designed to prevent contraction-induced muscle damage, offering potential benefits in improving muscle function for patients with ystrophinopathies. The drug is currently in Phase 2 trials, and has shown promising results in reducing muscle damage biomarkers​ ​ 🔸Another key program focuses on EDG-7500, an experimental therapy for hypertrophic cardiomyopathy (HCM). This drug is a selective sarcomere modulator designed to improve cardiac relaxation and contraction. The company initiated Phase 1 trials for EDG-7500 in 2023​. ​ 🔸Edgewise is dedicated to both advancing scientific research and engaging with patient communities, frequently collaborating with organizations such as the Muscular Dystrophy Association and the Parent Project Muscular Dystrophy 🔸The biotech company tested its drug, EDG-7500, in healthy volunteers and patients with obstructive hypertrophic cardiomyopathy. In this disease, a genetic mutation causes the heart ventricles to thicken. This limits cardiac function and exercise capacity. 🔸After a single dose, patients showed improved blood flow from the left ventricle. But sometimes drugs can do their job too well, suppressing cardiac function — a measure known as reduced left ventricular ejection fraction, or LVEF. But patients didn't show meaningful reductions in LVEF. 🎁Please hit the like button and 🎁Leave a comment to support our team! RISK DISCLAIMER: Trading Futures , Forex, CFDs and Stocks involves a risk of loss. Please consider carefully if such trading is appropriate for you. Past performance is not indicative of future results. Always limit your leverage and use tight stop loss.
NASDAQ:EWTXLong
by ProjectSyndicate
13
IBB d2 accumulation buy/hold setup 40% gains🔸Hello guys, today let's review 2daily chart for IBB . Entering re-accumulation stage now, expecting range bound trading during autumn time season. Range defined by range highs set at 135 usd and range lows at 117 usd. 🔸Similar fractal observed in 2018/2019. Faded into range after heavy spike, re-accumulation then 50% pump later during spring 2020. 🔸Recommended strategy bulls: wait for pullback to complete and reload low near range lows close to 111/113 usd (premium prices). TP1 bulls +20% gains, TP2 bulls +40% gains. buy/hold setup for patient traders. good luck! 🎁Please hit the like button and 🎁Leave a comment to support our team! RISK DISCLAIMER: Trading Futures , Forex, CFDs and Stocks involves a risk of loss. Please consider carefully if such trading is appropriate for you. Past performance is not indicative of future results. Always limit your leverage and use tight stop loss.
NASDAQ:IBBLong
by ProjectSyndicate
32
Biotech: textbook bullish continuation pattern breakoutBiotech was one of the first sectors in the market to show relative strength and catch some bids throughout the June bottoming process. IBB rallied 20% off the lows and then proceeded to consolidate sideways for 3 weeks. This Wednesday, IBB broke out of that consolidation with a gap up on heavy volume and is now finding more follow-through. Keep an eye on the old Feb/Apr highs around 135 which seems like the next target in this uptrend.
NASDAQ:IBB
by EvanMedeiros
1
IBB Biotech reversal pattern after bounce from TL; low may be inIBB bounced from the green pandemic support zone last March but have came back down to retest this zone. IBB has found support exactly on my GANN FAN line for several times before it breaks down & retested the violet downtrend line & bounced, making a reversal with a long hammer candle. IBB may close today above my GANN FAN line support confirming reversal . Closing the next few days above 124 the pre-pandemic high would give added confidence to the bottom reversal pattern. Next resistances are 127 & 136 to make a higher high. Not trading advice
NASDAQ:IBBLong
by xtremerider8
IBB D2: TOPPED OUT // correction looming // SHORT IT!(NEW)Why get subbed to to me on Tradingview? -TOP author on TradingView -15+ years experience in markets -Professional chart break downs -Supply/Demand Zones -TD9 counts / combo review -Key S/R levels -No junk on my charts -Frequent updates -Covering FX/crypto/US stocks -24/7 uptime so constant updates IBB D4: TOPPED OUT // correction looming // SHORT IT!(NEW) IMPORTANT NOTE: speculative setup. do your own due dill. use STOP LOSS. don't overleverage. 🔸 Summary and potential trade setup ::: IBB / Biotech sector is maxed out ::: previously a steep 100% run up ::: unsustainable ::: hype is already gone ::: 30/40% correction incoming for IBB ::: VERY limited upside from here ::: rotate out of biotech now ::: expecting correction MODE ::: alternatively you can also SHORT IT ::: SHORT IT 25% gains at least short-term ::: more coming over next few months ::: unsustainable gains, game over now ::: distribution at the TOP setup ::: spells MAJOR trouble for the BULLS ::: BEAR cubs will turn into GRIZZLY ::: expecting CORRECTION to last next 4-8 months ::: distribution at the top in progress ::: will lose up to 40% during correction ::: There is no upside in this market ::: Get out / trim exposure / or SHORT IT ::: Game over bulls and market will shift ::: into BEAR mode September/October 2020 ::: either way setting up for 40%+ correction ::: 4-8 months of correction incoming soon ::: better be prepared in advance ::: when there's GREED there's also PAIN ::: good luck traders 🔸 Supply/Demand Zones ::: N/A ::: N/A 🔸 Other noteworthy technicals/fundies ::: TD9 /Combo update: N/A ::: Sentiment: BEARS ::: Sentiment outlook short-term: BEARISH RISK DISCLAIMER: Trading Crypto, Futures , Forex, CFDs and Stocks involves a risk of loss. Please consider carefully if such trading is appropriate for you. Past performance is not indicative of future results. Always limit your leverage and use tight stop loss.
NASDAQ:IBBShort
by ProjectSyndicate
3
IBB D2: TOPPED OUT // correction looming // SHORT IT!(NEW)Why get subbed to to me on Tradingview? -TOP author on TradingView -15+ years experience in markets -Professional chart break downs -Supply/Demand Zones -TD9 counts / combo review -Key S/R levels -No junk on my charts -Frequent updates -Covering FX/crypto/US stocks -24/7 uptime so constant updates IBB D2: TOPPED OUT // correction looming // SHORT IT!(NEW) IMPORTANT NOTE: speculative setup. do your own due dill. use STOP LOSS. don't overleverage. 🔸 Summary and potential trade setup ::: IBB / Biotech sector is maxed out ::: previously a steep 100% run up ::: unsustainable ::: hype is already gone ::: 30/40% correction incoming for IBB ::: VERY limited upside from here ::: rotate out of biotech now ::: expecting correction MODE ::: alternatively you can also SHORT IT ::: SHORT IT 25% gains at least short-term ::: more coming over next few months ::: unsustainable gains, game over now ::: distribution at the TOP setup ::: spells MAJOR trouble for the BULLS ::: BEAR cubs will turn into GRIZZLY ::: expecting CORRECTION to last next 4-8 months ::: distribution at the top in progress ::: will lose up to 40% during correction ::: There is no upside in this market ::: Get out / trim exposure / or SHORT IT ::: Game over bulls and market will shift ::: into BEAR mode September/October 2020 ::: either way setting up for 40%+ correction ::: 4-8 months of correction incoming soon ::: better be prepared in advance ::: when there's GREED there's also PAIN ::: good luck traders 🔸 Supply/Demand Zones ::: N/A ::: N/A 🔸 Other noteworthy technicals/fundies ::: TD9 /Combo update: N/A ::: Sentiment: BEARS ::: Sentiment outlook short-term: BEARISH RISK DISCLAIMER: Trading Crypto, Futures , Forex, CFDs and Stocks involves a risk of loss. Please consider carefully if such trading is appropriate for you. Past performance is not indicative of future results. Always limit your leverage and use tight stop loss.
NASDAQ:IBBShort
by ProjectSyndicate
9
Amarin Corporation: A Hidden GemGood afternoon. I would be glad if you subscribe to me in TradingView so you can be the first to read my new ideas. Overly grateful for your likes. In the comments, you can ask questions about the company. Summary Technical analysis On the chart, we can see the imminent completion of corrective wave 2 and the appearance of impulse wave 3. Several indicators support the uptrend, including the RSI indicator. In addition, this indicator confirms the Elliott Wave labeling. On the 1D chart, we can see an open gap in the area of $8.4-12.8 per share. The company's shares are currently in an uptrend. In addition, Amarin shares are just above the EMA 55 and EMA 89, which also confirms the uptrend. Fundamental Analysis You can read a complete fundamental analysis of the company in my analytical article in SA. Conclusion Considering the above factors, I believe that the growth of Amarin shares will continue. Disclosure: This article may not take into account all the risks and catalysts for the stocks described in it. Any part of this analytical article is provided for informational purposes only, does not constitute an individual investment recommendation, investment idea, advice, offer to buy or sold securities, or other financial instruments. The completeness and accuracy of the information in the analytical article are not guaranteed. If any fundamental criteria or events change in the future, I do not assume any obligation to update this article.
NASDAQ:AMRNLong
by UnknownUnicorn28205834
1
OptiNose: Maximum OptimismGood afternoon. I would be glad if you subscribe to me in TradingView so you can be the first to read my new ideas. Overly grateful for your likes. In the comments, you can ask questions about the company. Summary: Technical analysis: On the chart, we can see the completion of corrective wave 2 and the emergence of impulse wave 3. According to the RSI indicator, we can see an uptrend, which confirms the labeling of the Elliott waves. On the 1D chart, we can see an open gap in the area of $6-7 per share. Currently, the company's shares are in the area of the downtrend breakout. In addition, Optinose shares have broken through EMA 55 and are just below EMA 89. Fundamental Analysis: You can read a complete fundamental analysis of the company in my analytical article in SA. Conclusion Considering the above factors, I believe that the growth of Optinose shares will continue. Disclosure: This article may not take into account all the risks and catalysts for the stocks described in it. Any part of this analytical article is provided for informational purposes only, does not constitute an individual investment recommendation, investment idea, advice, offer to buy or sold securities, or other financial instruments. The completeness and accuracy of the information in the analytical article are not guaranteed. If any fundamental criteria or events change in the future, I do not assume any obligation to update this article.
NASDAQ:OPTNLong
by UnknownUnicorn28205834
1
BioTech And Stay At Home Stocks Show Delta WorriesThe major indices like AMEX:SPY NASDAQ:QQQ have held up well despite talks of the delta variant though peeling back a few layers shows that there are underlying concerns. Many biotech, cloud software, and stay at home names are showing strong chart patterns that are poised to move higher. Among those names are NASDAQ:IBB NASDAQ:GILD NASDAQ:ZM CRM and NYSE:SNOW . Meanwhile other stay at home related stocks have already run wild altogether - NASDAQ:ADBE NASDAQ:DOCU AMEX:IGV NASDAQ:BNTX NASDAQ:MRNA . Investors should be cautious as these stocks may be signaling weakness in Q4 as variant fears are causing more and more corporations to require masks and as inflation gets out of hand on Main street, which could ultimately slow growth as the middle and lower class are forced to tighten belts.
NASDAQ:IBB
by aaronbasile
OPTINOSE: "Rocket launch"Greetings Summary: Fundamental Analysis: Full year 2020 XHANCE prescriptions increased 70% compared to full year 2019 Company expects top-line results from one of its clinical trials evaluating XHANCE as a potential treatment for Chronic Sinusitis by the end of 2021 In April 2021, the Company expects to initiate a randomized, proof of concept study in subjects who have tested positive for SARS-CoV-2 infection, are recently infected, and who have mild or no symptoms. This pilot study being conducted in Mexico will evaluate both the magnitude and duration of viral load reduction after a single dose of OPN-019. The Company expects top-line results from this study in second quarter 2021. The company shows stable revenue growth from year to year. Technical analysis: From May 2020 to the end of June 2020, the 5th wave movement was completed.After that, a correction began. At the moment, the company's shares are in the oversold zone according to the RSI indicator. The company has several open gaps, namely in the following areas: $ 6-7, $ 10-11 per share. At the moment, the company's shares are at a strong support level . Disclosure: I am/we are long OPTN. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from TradingView). I have no business relationship with any company whose stock is mentioned in this article.
NASDAQ:OPTNLong
by UnknownUnicorn11885613
1
Fluidigm is the leader in mass cytometry and microfluidicsGreetings Summary: Fundamental Analysis: Fluidigm Selected for $37 Million Project under National Institutes of Health RADx Initiative.Fluidigm among First Seven Companies to Advance in Historic and Rapidly Instituted Program to Support Development and Commercialization of Innovative COVID-19 Testing Technologies Fluidigm is a leader in mass cytometry. According to market research and Fluidigm, the mass cytometry market reached 2.7 billion with CAGR at 26% by 2025. The Biden administration plans to spend about $ 1.6 billion on expanding Covid-19 testing programs. Fluidigm Announces Collaboration with Zhejiang PuLuoTing Health Technology Co. Ltd to Market Fluidigm CyTOF Technology to Clinical Labs in China.According to company and third-party estimates, the addressable market for flow cytometry analysis in blood cancer in China is approximately $100 million for 2021–2023, and is growing at a double-digit rate. The company shows stable revenue growth from year to year. Technical analysis: From March 2020 to the end of September 2020, the 5th wave movement was completed.After that, a correction began, namely a double three, consisting of 2 zigzags. At the moment, the company's shares are in the oversold zone according to the RSI indicator. The company has several open gaps, namely in the following areas: $ 10-11, $ 15-19, $ 30-36 per share. At the moment, the company's shares are at a strong support level. Disclosure: I am/we are long FLDM. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from TradingView). I have no business relationship with any company whose stock is mentioned in this article.
FLong
by UnknownUnicorn11885613
1
CDXC 4.8: Small Float Biotech backed by Li Ka Shing In this market where SPEC trades at billions with NO revenue, I like CDXC though I may be early. Yes it's not TSLA, yes Value does not work in this market but With a tiny market cap of 290 mil and revenue growth at 40% (still early-stage market), I am betting with Li Ka Shing, one of the richest and other top 20 institutions including Blackrock who collectively owns 55% of the stock. Short interest is small at 7%. The better story is that the stock has been basing for a long time, and technicals are improving. I don't want to wait for breakout then buy as by then I would be paying too much a premium. So good enough for me with the IMPROVING technicals and a largely positive trend, and a real growth story. investors.chromadex.com asia.nikkei.com Top Shareholders Top 25 shareholders own 54.62% of the company Ownership Name Shares Current Value Change % Portfolio % 10.49% Ka-shing Li 6,500,937 $31.4m 0% no data 10.29% Hoi Shuen Chau 6,377,783 $30.8m 0% no data 4.53% BlackRock, Inc. 2,804,544 $13.5m -0.81% no data 3.97% The Vanguard Group, Inc. 2,461,485 $11.9m 9.03% no data 3.8% Li Ka Shing (Global) Foundation, Endowment Arm 2,353,139 $11.4m 0% 3.25% 3.11% Phillip and Patricia Frost Philanthropic Foundation, Inc, Endowment Arm 1,929,542 $9.3m 0% 42.91% 2.76%
NASDAQ:CDXCLong
by Jonas99
2
IBB H4: 25% gains TP HIT / congrats! (RECAP/REVIEW)Why get subbed to me on Tradingview? -TOP author on TradingView -15+ years experience in markets -Professional chart break downs -Supply/Demand Zones -TD9 counts / combo review -Key S/R levels -No junk on my charts -Frequent updates -Covering FX/crypto/US stocks -24/7 uptime so constant updates IBB H4: BEST Level to BUY/HOLD 25% gains(SL/TP)(STOCKS) IMPORTANT NOTE: speculative setup. do your own due dill. use STOP LOSS. don't overleverage. Congrats if you followed the original setup. click play to recap it. razor sharp entry. 🔸 Summary and potential trade setup ::: IBB 4hour chart review and outlook ::: Biotech sector outperforming market ::: due to coronavirus ::: so far in 2020 YTD gains ::: BUY dips / buy the pullback ::: noteworthy compression now ::: BUY close to 130 USD ::: is the best strategy BULLS ::: wait for pullback/dips and BUY IT ::: recommended strategy: BUY LOW 130 USD ::: SL 5% TP is 155/160 USD +25% gains ::: BUY/HOLD setup ::: DO NOT expect overnight gains ::: This is stock market :::Not casino in Macau 🔸 Supply/Demand Zones . N/A 🔸 Why should I follow your setups? :::Check track record it's all been posted ::: MRNA 200%+ gains, NVAX 300% gains, REG 60% ::: AMD 40% gains and a lot more in 2020
NASDAQ:IBBLong
by ProjectSyndicate
10